工作经历
1997年6月安徽师范大学化学系本科毕业；2002年6月在中国科学院上海药物研究所获得有机化学博士学位，后留所担任助理研究员；2004年9月-2006年6月在美国伊利诺伊大学芝加哥分校生药和药物化学系从事博士后研究；2006年7月-2009年4月在制药公司担任高级研发主管；2009年5月起加入复旦大学药学院，2019年5月转入人类表型组研究院担任科研副院长，2024年起担任教学副院长。
研究方向
从事药物表型组学研究，聚焦心脑血管疾病、高原脑水肿和高原肺水肿等重大疾病，探索发现新作用机制和靶点，进一步通过药物化学手段进行结构优化，提高成药性，研发候选药物进入临床研究。主持国家自然科学基金，科技部新药创制重大专项子课题等省部级基金13项；在Cell Death Differ., Adv. Sci., J. Med. Chem.等期刊发表SCI论文60余篇；已授权国内专利15项、美国专利1项。其中作为主要发明人研制的化药1.1类抗肿瘤新药喜诺替康（ZL 03142241.1）原料药和注射剂于2011年分别获得临床试验批件（2011L00694，2011L00695），并已转让给江苏正大天晴药业股份有限公司实现成果转化。
获奖情况
2012年获得上海药学科技奖二等奖(第3完成人)
2023年入选东方英才计划（拔尖）
招生专业
生物学（研究方向：药物表型组学）；生物与医药（研究方向：药物靶标筛选）；药物化学
代表论文
1. Heyanhao Zhang, Yuyu Zhang, Yibo Chen, Wen Zhong, Subei Tan, Jinghuan Wang, Huanren Yan, Ning Yan, Mengjia Lin, Xinhua Liu*, Jun Chang*. Procyanidin B3 and its derivatives alleviate neuronal injury by targeting G3BP1 for ischemic stroke therapy. Advanced Science 2025, e09781.
2. Yuyu Zhang, Jinghuan Wang, Mengting He, Jiayao Liu, Jialin Zhao, Jintao He, Caiyun Wang, Yuhui Li, Chenxi Xiao, Chunxiang Fan*, Jun Chang*, Xinhua Liu*. Hypobaric hypoxia-driven energy metabolism disturbance facilitates vascular endothelial dysfunction. Redox Biology 2025, 84, 103675.
3. Caiyun Wang, Wu-gui Chen, Honghong Chen, Jialin Zhao, Jintao He, Yajie Hu, Mengting He, Yuyu Zhang, Cheng-shou Lin*, Jun Chang*, Xinhua Liu*. Exercise Improves Hypobaric Hypoxia-Induced Skeletal Muscle Dysfunction via SIRT1-Mediated Myotube and Mitochondrial Remodeling. Journal of Advanced Research 2025, https://doi.org/10.1016/j.jare.2025.08.022.
4. Hai-bi Su, Jing-huan Wang, Yu-yu Zhang, Jie Xu, Jia-yao Liu, Yu-hui Li, Chen-xi Xiao, Cai-yun Wang, Jun Chang*, Xin-hua Liu*. Inhibition of Setd7 protects against cardiomyocyte hypertrophy via inhibiting lipid oxidation. Acta Pharmacologica Sinica 2025, https://doi.org/10.1038/s41401-025-01626-3.
5. Yuhui Li, Mengting He, Jie Xu, Jiayao Liu, Chenxi Xiao, Yajie Hu, Honghong Chen, Jun Chang*, Xinhua Liu*. Hypoxia exposure promotes Th17 cell differentiation through Activin A-PKM2 axis to exacerbate autoimmune and autoinflammatory diseases. FASEB Journal 2025, 39, e70696.
6. Jinghuan Wang, Subei Tan, Yuyu Zhang, Jie Xu, Yuhui Li, Qianwen Cheng, Chen Ding*, Xinhua Liu*, Jun Chang*. Set7/9 aggravates ischemic brain injury via enhancing glutamine metabolism in a blocking Sirt5 manner. Cell Death & Differentiation 2024, 31, 511-523.
7. Mei-Lin Tang, Xiao-Yu Xiong, Heyanhao Zhang, Yun-Zhi Wang, Rong-Qian Cheng, Jian-Ping Zuo, Lin Jin*, Ze-Min Lin*, Jun Chang*. From hit to lead: Discovery of first-in-class furanone glycoside D228 derived from Chimonanthus salicifolius for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry 2024, 67, 17101-17123.
8. Ganfei Xu, Juan Yu, Jiacheng Lyu, Mengna Zhan, Jie Xu, Minjing Huang, Rui Zhao, Yan Li, Jiajun Zhu, Subei Tan, Peng Ran, Zhenghua Su, Xinhua Liu, Jianyuan Zhao, Hongwei Zhang*, Chen Xu*, Jun Chang*, Yingyong Hou*, Chen Ding*. Proteogenomic landscape of breast ductal carcinoma reveals tumor progression characteristics and therapeutic targets. Advanced Science 2024, e01041.
9. Wen Zhong, Ye-jun Dong, Chen Hong, Yu-hui Li, Chen-xi Xiao, Xin-hua Liu*, Jun Chang*. ASH2L upregulation contributes to diabetic endothelial dysfunction in mice through STEAP4-mediated copper uptake. Acta Pharmacologica Sinica 2024, 45, 558-569.
10. Heyanhao Zhang, Jintao He, Rongqian Cheng, Huanren Yan, Mei-Lin Tang, Jun Chang*. Optimization for the Preparation of Procyanidin B3: Strategy for Gram-Scale and Stereoselective Formation of 4,8-Interflavan Bonds. Organic Process Research & Development 2024, 28, 2958-2971.
